TGRX-678 US Phase I for Subjects With Refractory or Advanced Chronic Myelogenous Leukemia
Status:
Recruiting
Trial end date:
2027-06-30
Target enrollment:
Participant gender:
Summary
The purpose of this single-arm, open-label, dose escalation + cohort expansion study is to
evaluate the safety, tolerability, pharmacokinetic and preliminary efficacy of TGRX-678 in
Chronic Myelogenous Leukemia patients who had failure with or are intolerant to TKI
treatments.